scholarly journals Cog-Pro: Impact of new generation hormono-therapy on cognitive functions in elderly patients treated for a metastatic prostate cancer

2016 ◽  
Vol 27 ◽  
pp. vi261
Author(s):  
F. Joly ◽  
M. Lange ◽  
N. Heutte ◽  
A. Leconte ◽  
I. Léger ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Elderly Patients ◽  
Cognitive Functions ◽  
Metastatic Prostate Cancer ◽  
New Generation

Prevalence of first and subsequent skeletal-related events (SREs) in U.S. elderly patients with metastatic prostate cancer (mPC).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e16006-e16006
Author(s):  
Arif Hussain ◽  
Abdulla M. Abdulhalim ◽  
C. Daniel Mullins ◽  
Yi Qian ◽  
Jorge Arellano ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Elderly Patients ◽  
Metastatic Prostate Cancer ◽  
Skeletal Related Events

scholarly journals Effects of androgen deprivation therapy on cognitive functions in patients with metastatic prostate cancer: A multicentric, prospective study of the Society of Urological Surgery Andrology group

2020 ◽  
Author(s):  
Onder Cinar ◽  
Tahsin Turunc ◽  
Ilke Onur Kazaz ◽  
Omer Yildirim ◽  
Hasan Deliktas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Depressive Symptoms ◽  
Androgen Deprivation Therapy ◽  
Cognitive Functions ◽  
Metastatic Prostate Cancer ◽  
Verbal Learning ◽  
Androgen Deprivation ◽  
California Verbal Learning Test ◽  
The Mean ◽  
Learning Test

Abstract Aims of the study: The aim of this study was to investigate the impact of testosterone deficiency on cognitive functions in metastatic prostate cancer patients receiving androgen deprivation therapy (ADT). Methods: In this multicentric prospective study, 65 metastatic prostate cancer patients were evaluated. Demographic and clinical data were recorded. Cognitive functions were assessed using the Symbol Digit Modalities Test, the California Verbal Learning Test Second Edition, the Brief Visuospatial Memory Test - Revised, and the Trail Making Test. Depressive symptoms were assessed using the Beck Depression Inventory. Cognitive functions and depressive symptoms were recorded before the androgen deprivation therapy and at the 3- and 6-month follow ups. Results: At the basal cognitive assessment, the mean Symbol Digit Modalities Test, the California Verbal Learning Test Second Edition, the Brief Visuospatial Memory Test - Revised scores were 25.84 ± 17.54, 32.68 ± 10.60, and 17.63 ± 11.23, respectively, and the mean time for the Trail Making Test was 221.56 ± 92.44 s., and were similar at the 3-month, and 6-month controls (p > 0.05). The mean pretreatment, third and sixth month testosterone levels were 381.40 ± 157.53 ng/dL, 21.61 ± 9.09 ng/dL, and 12.25 ± 6.45 ng/dL (p < 0.05), and the total PSA levels were 46.46 ± 37.83 ng/mL, 1.41 ± 3.31 ng/mL, and 0.08 ± 0.14 ng/mL (p < 0.05), respectively. Conclusion: The ADT in patients with metastatic prostate cancer does not affect patients’ cognitive functions and depressive symptoms. However, further prospective randomized studies with higher cohorts and longer follow up periods are needed.

scholarly journals Apalutamide – 10 clinically important facts

Oncoreview ◽  
2021 ◽  
Vol 11 (3(43)) ◽  
pp. 85-88
Author(s):  
Kajetan Juszczak ◽  
Tomasz Drewa
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Hormone Therapy ◽  
Metastatic Prostate Cancer ◽  
Therapeutic Options ◽  
Testosterone Levels ◽  
New Generation ◽  
Receptor Inhibitor

Apalutamide belongs to the ARTA group. This drug is a new generation selective androgen receptor inhibitor. Patients with prostate cancer develop resistance to castration testosterone levels over timeduring hormone therapy. Therefore, it is necessary to consider additional therapeutic options based on drugs from the ARTA group. Apalutamide is used in the treatment of patients with non-metastatic as well as metastatic prostate cancer. This article presents the most important clinical facts about apalutamide.

Sign in / Sign up

Export Citation Format

Share Document